Linden Capital Partners Acquires Alcresta Therapeutics

Linden Capital Partners Acquires LifeStyles Healthcare

December 1, 2022

Consumer Products

Linden Capital Partners has acquired LifeStyles Healthcare, a global sexual health and wellness platform, from a consortium of investors including Trustar Capital and Humanwell Healthcare. The deal excludes LifeStyles' Chinese operations (including the Jissbon brand), which will be retained by the selling shareholders; Linden has named Laurent Faracci as incoming CEO and Ron Fugate as Chairman to drive commercial, brand, and innovation-led growth.

Aileron Therapeutics Acquires Lung Therapeutics

October 31, 2023

Biotechnology

Aileron Therapeutics, Inc. (NASDAQ: ALRN) completed a stock-for-stock acquisition of Lung Therapeutics, Inc., bringing the clinical-stage pulmonary and fibrosis-focused pipeline (including lead candidate LTI-03) into Aileron's portfolio. Immediately after the acquisition Aileron arranged a private placement led by Bios Partners (with participation from Nantahala Capital and others) to raise approximately $18 million to fund ongoing development, including a Phase 1b trial of LTI-03.

Concord Health Partners Leads Growth Financing in Accelus

May 29, 2025

Medical Devices

Accelus, a Palm Beach Gardens-based medical technology company specializing in expandable spinal implant technologies, closed a new equity financing round led by healthcare-focused investment firm Concord Health Partners. The capital will support Accelus's U.S. commercial expansion and further development of its spinal implant product pipeline.

Linden Capital Partners Majority Recapitalizes BioIVT from Arsenal Capital Partners

October 5, 2021

Healthcare Services

Linden Capital Partners has completed a majority recapitalization of BioIVT, a Westbury, New York-based provider of mission-critical biological specimens and value-added services, alongside continuing investor Arsenal Capital Partners and BioIVT management. Financial terms were not disclosed; Linden will support BioIVT’s plans to accelerate organic growth and pursue acquisitions, with debt financing provided by funds managed by Ares Management’s Credit Group and Golub Capital.

Martis Capital Invests in Alcanza Clinical Research

October 3, 2022

Healthcare Services

Martis Capital, a middle‑market healthcare private equity firm, announced an investment in Alcanza Clinical Research, a clinical research site network platform founded in December 2021. Martis will support Alcanza's national expansion and capability build‑out — Alcanza has already consolidated five clinical research sites across multiple states and will pursue additional acquisitions and strategic partnerships to scale Phase I–IV capabilities.

BioCryst Pharmaceuticals Acquires Astria Therapeutics

January 26, 2026

Biotechnology

BioCryst Pharmaceuticals has completed its acquisition of Astria Therapeutics for an implied transaction value of approximately $700 million, financed with cash on hand and a ~$396.6 million facility provided by funds managed by Blackstone plus ~37.3 million BioCryst shares issued to Astria equity holders. The deal adds Astria's Phase 3 long-acting plasma kallikrein inhibitor navenibart to BioCryst's hereditary angioedema (HAE) portfolio and provides Astria's early-stage atopic dermatitis program (STAR0310) for which BioCryst will pursue strategic alternatives.